Recent News for HEB - Hemispherx BioPharma, Inc.

Date Title
Apr 23 MicroCap Review Magazine Spring 2019 Issue Now Available
Apr 22 Hemispherx Biopharma Names Ellen Lintal as New Chief Accounting Officer
Apr 13 Some Hemispherx Biopharma (NYSEMKT:HEB) Shareholders Have Copped A 96% Share Price Wipe Out
Apr 2 Hemispherx Announces the First Participant Received Initial Dosing in Breast Cancer Clinical Trial Using Hemispherx’ Ampligen and Pembrolizumab
Apr 1 Hemispherx Biopharma reports FY results
Apr 1 Hemispherx Reports 2018 Year-end Financial Results
Mar 13 Hemispherx Bio up 8% on Ampligen progress
Mar 13 Hemispherx Biopharma Announces Significant Progress in its Ampligen Pancreatic Cancer Program and Multiple Ampligen+Checkpoint Blockade Immuno-Oncology Programs
Mar 6 Hemispherx Biopharma Announces $5.3 Million in Expected Gross Proceeds from Recently Expired Rights Offering
Feb 28 Hemispherx Announces Dutch Health Inspectorate Approval to Extend the Ampligen Pancreatic Cancer Early Access Program Until March 2020
Feb 28 Hemispherx Biopharma Announces Extension of Rights Offering Period to March 5, 2019
Feb 27 Hemispherx Biopharma Updates the Terms of Previously Announced Rights Offering and Announces Senior Management and Directors All Plan to Participate in the Offering  
Feb 15 Hemispherx Biopharma Announces Commencement of Rights Offering Subscription Period
Feb 12 Hemispherx Biopharma Reminds Investors of Today’s Deadline to be a Stockholder of Record
Feb 11 Hemispherx Biopharma Announces Commencement of a New 45 Subject Clinical Trial Combining Ampligen and Merck’s Keytruda in the Treatment of Recurrent Ovarian Cancer
Feb 8 Hemispherx Biopharma: Selling New Warrants At Uncertain Times
Feb 7 Hemispherx Bio readies $8M rights offering
Feb 6 Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering
Jan 31 Hemispherx Biopharma Shares CEO’s Presentation at the NobleConXV Conference
Jan 30 Hemispherx Biopharma (HEB) Presents At Noble Capital Markets 15th Annual Investor Conference - Slideshow
Jan 28 Recent Analysis Shows The Chemours, Inter Parfums, Newmont Mining, Sanderson Farms, NGL Energy Partners LP, and Hemispherx BioPharma Market Influences — Renewed Outlook, Key Drivers of Growth
Jan 24 REPEAT - Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
Jan 23 Hemispherx Biopharma’s CEO to Present at the 15th Annual NobleConXV Conference
Jan 8 Hemispherx Bio up 22% on Ampligen + Keytruda studies
Jan 8 Hemispherx Biopharma Announces IRB Approval of Clinical Study in Metastatic Triple Negative Breast Cancer in Collaboration with Roswell Park Comprehensive Cancer Center

Back to the Main HEB Page...